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The Wellcome Trust has awarded £4.7 million to the
European Bioinformatics Institute (EBI) to support the
transfer of a large collection of information on the prop-
erties and activities of drugs and a large set of drug-like
small molecules from BioFocus DPI, part of the publicly
listed company Galapagos to the public domain.
The databases will be incorporated into EBI's collection of
open-access data resources for biomedical research and
will be maintained by a newly established team at the EBI.
These data lie at the heart of translating information from
the human genome into successful new drugs in the
clinic.
The databases to be brought into the public domain
include DrugStore™ (database of known drugs), StARL-
ITe™ (database of known compounds and their effects),
Strudle™ (binding site drugability), and Kinase SARfari™
and GPCR SARfari™ (informatics systems for the most
widely used target classes in drug discovery). The main
database, StARLITe, on Drug-Target interactions alone has
hundreds of thousands of interaction data points manu-
ally curated from the medicinal chemistry literature.
A new team leader will be appointed to support the new
resource and my group will provide the chemoinformatics
expertise to move the underlying analysis software into
the open source world. The Chemistry Development Kit
(CDK) will play a major role both in freeing the QSAR
code as well as in providing (sub-) structure and similarity
searching to the database.
The transfer will empower academia to participate in the
first stages of drug discovery for all therapeutic areas,
including major diseases of the developing world. In
future it could also result in improved prediction of drug
side-effects and spark all kinds of new academic research
directions.
This talk will outline the resources to be brought into the
public domain, discuss the integration into EBI resources
and give a view on our future plans of developments.
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